Loading…
P-glycoprotein and alloimmune T-cell activation
P-glycoprotein (P-gp), the human multidrug resistant (MDR1) gene product and cancer multidrug resistance-associated adenosine triphosphate (ATP)-binding cassette (ABC) transporter, is physiologically expressed on peripheral blood mononuclear cells, but its role in cellular immunity is only beginning...
Saved in:
Published in: | Clinical and Applied Immunology Reviews 2003-07, Vol.4 (1), p.3-14 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4112-b2f302f31e1130e9aceac73892a868e2a6c33efa553262d3870ebe5b82f70fcd3 |
---|---|
cites | cdi_FETCH-LOGICAL-c4112-b2f302f31e1130e9aceac73892a868e2a6c33efa553262d3870ebe5b82f70fcd3 |
container_end_page | 14 |
container_issue | 1 |
container_start_page | 3 |
container_title | Clinical and Applied Immunology Reviews |
container_volume | 4 |
creator | Pendse, Shona S. Briscoe, David M. Frank, Markus H. |
description | P-glycoprotein (P-gp), the human multidrug resistant (MDR1) gene product and cancer multidrug resistance-associated adenosine triphosphate (ATP)-binding cassette (ABC) transporter, is physiologically expressed on peripheral blood mononuclear cells, but its role in cellular immunity is only beginning to be elucidated. A role of P-gp in the secretion of several T-cell and antigen presenting cell-derived cytokines has been described, and additional functions of the molecule have been identified in lymphocyte survival and antigen presenting cell differentiation. Taken together, these findings provide compelling evidence that P-gp serves several distinct functions in the initiation of primary immune responses, and a critical role of the molecule in functional alloimmune responses is now established. Here, we will review the current understanding of P-gp function in alloimmune T-cell activation via both T-cell and antigen presenting cell-dependent mechanisms, which is relevant to the field of clinical transplantation, where P-gp has been found to be a marker of acute and chronic allograft rejection. Indeed, current in vitro findings raise the possibility that P-gp could represent a novel therapeutic target in acute and chronic allograft rejection, the major causes of allograft dysfunction and ultimate graft loss. |
doi_str_mv | 10.1016/S1529-1049(03)00007-2 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3121004</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1529104903000072</els_id><sourcerecordid>1835552142</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4112-b2f302f31e1130e9aceac73892a868e2a6c33efa553262d3870ebe5b82f70fcd3</originalsourceid><addsrcrecordid>eNqFkV1LwzAUhoMoOqc_QdmV6EVdTtI07Y0iwy8YKKjXIUtPNdI2M-kG_nsz94HeaCAkkOd9T855CTkCeg4UsuETCFYkQNPilPIzGpdM2BbpAc9EwkQmt-N9jeyR_RDeadQVabpL9hhIWkiR9sjwMXmtP42betehbQe6LQe6rp1tmlmLg-fEYF0PtOnsXHfWtQdkp9J1wMPV2ScvN9fPo7tk_HB7P7oaJyYFYMmEVZzGDQjAKRbaoDaS5wXTeZYj05nhHCstBGcZK3kuKU5QTHJWSVqZkvfJxdJ3Ops0WBpsO69rNfW20f5TOW3V75fWvqlXN1ccGFCaRoOTlYF3HzMMnWpsWDSjW3SzoBjNmJRCRvD0TxByLoRgkLKIiiVqvAvBY7X5D1C1SEV9p6IWI1eUq-9U1EJ3_LOZjWodQwQulwDGkc4tehWMxdZgaT2aTpXO_lPiC8kEm_c</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835552142</pqid></control><display><type>article</type><title>P-glycoprotein and alloimmune T-cell activation</title><source>ScienceDirect Freedom Collection</source><source>Wiley-Blackwell Read & Publish Collection</source><source>PubMed Central</source><creator>Pendse, Shona S. ; Briscoe, David M. ; Frank, Markus H.</creator><creatorcontrib>Pendse, Shona S. ; Briscoe, David M. ; Frank, Markus H.</creatorcontrib><description>P-glycoprotein (P-gp), the human multidrug resistant (MDR1) gene product and cancer multidrug resistance-associated adenosine triphosphate (ATP)-binding cassette (ABC) transporter, is physiologically expressed on peripheral blood mononuclear cells, but its role in cellular immunity is only beginning to be elucidated. A role of P-gp in the secretion of several T-cell and antigen presenting cell-derived cytokines has been described, and additional functions of the molecule have been identified in lymphocyte survival and antigen presenting cell differentiation. Taken together, these findings provide compelling evidence that P-gp serves several distinct functions in the initiation of primary immune responses, and a critical role of the molecule in functional alloimmune responses is now established. Here, we will review the current understanding of P-gp function in alloimmune T-cell activation via both T-cell and antigen presenting cell-dependent mechanisms, which is relevant to the field of clinical transplantation, where P-gp has been found to be a marker of acute and chronic allograft rejection. Indeed, current in vitro findings raise the possibility that P-gp could represent a novel therapeutic target in acute and chronic allograft rejection, the major causes of allograft dysfunction and ultimate graft loss.</description><identifier>ISSN: 1529-1049</identifier><identifier>EISSN: 1365-2567</identifier><identifier>EISSN: 1878-5441</identifier><identifier>DOI: 10.1016/S1529-1049(03)00007-2</identifier><identifier>PMID: 21709754</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antigen presentation ; P-glycoprotein ; T-cell activation</subject><ispartof>Clinical and Applied Immunology Reviews, 2003-07, Vol.4 (1), p.3-14</ispartof><rights>2003 Elsevier Inc.</rights><rights>2003 Elsevier Inc. All rights reserved. 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4112-b2f302f31e1130e9aceac73892a868e2a6c33efa553262d3870ebe5b82f70fcd3</citedby><cites>FETCH-LOGICAL-c4112-b2f302f31e1130e9aceac73892a868e2a6c33efa553262d3870ebe5b82f70fcd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21709754$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pendse, Shona S.</creatorcontrib><creatorcontrib>Briscoe, David M.</creatorcontrib><creatorcontrib>Frank, Markus H.</creatorcontrib><title>P-glycoprotein and alloimmune T-cell activation</title><title>Clinical and Applied Immunology Reviews</title><addtitle>Clin Appl Immunol Rev</addtitle><description>P-glycoprotein (P-gp), the human multidrug resistant (MDR1) gene product and cancer multidrug resistance-associated adenosine triphosphate (ATP)-binding cassette (ABC) transporter, is physiologically expressed on peripheral blood mononuclear cells, but its role in cellular immunity is only beginning to be elucidated. A role of P-gp in the secretion of several T-cell and antigen presenting cell-derived cytokines has been described, and additional functions of the molecule have been identified in lymphocyte survival and antigen presenting cell differentiation. Taken together, these findings provide compelling evidence that P-gp serves several distinct functions in the initiation of primary immune responses, and a critical role of the molecule in functional alloimmune responses is now established. Here, we will review the current understanding of P-gp function in alloimmune T-cell activation via both T-cell and antigen presenting cell-dependent mechanisms, which is relevant to the field of clinical transplantation, where P-gp has been found to be a marker of acute and chronic allograft rejection. Indeed, current in vitro findings raise the possibility that P-gp could represent a novel therapeutic target in acute and chronic allograft rejection, the major causes of allograft dysfunction and ultimate graft loss.</description><subject>Antigen presentation</subject><subject>P-glycoprotein</subject><subject>T-cell activation</subject><issn>1529-1049</issn><issn>1365-2567</issn><issn>1878-5441</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqFkV1LwzAUhoMoOqc_QdmV6EVdTtI07Y0iwy8YKKjXIUtPNdI2M-kG_nsz94HeaCAkkOd9T855CTkCeg4UsuETCFYkQNPilPIzGpdM2BbpAc9EwkQmt-N9jeyR_RDeadQVabpL9hhIWkiR9sjwMXmtP42betehbQe6LQe6rp1tmlmLg-fEYF0PtOnsXHfWtQdkp9J1wMPV2ScvN9fPo7tk_HB7P7oaJyYFYMmEVZzGDQjAKRbaoDaS5wXTeZYj05nhHCstBGcZK3kuKU5QTHJWSVqZkvfJxdJ3Ops0WBpsO69rNfW20f5TOW3V75fWvqlXN1ccGFCaRoOTlYF3HzMMnWpsWDSjW3SzoBjNmJRCRvD0TxByLoRgkLKIiiVqvAvBY7X5D1C1SEV9p6IWI1eUq-9U1EJ3_LOZjWodQwQulwDGkc4tehWMxdZgaT2aTpXO_lPiC8kEm_c</recordid><startdate>20030701</startdate><enddate>20030701</enddate><creator>Pendse, Shona S.</creator><creator>Briscoe, David M.</creator><creator>Frank, Markus H.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20030701</creationdate><title>P-glycoprotein and alloimmune T-cell activation</title><author>Pendse, Shona S. ; Briscoe, David M. ; Frank, Markus H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4112-b2f302f31e1130e9aceac73892a868e2a6c33efa553262d3870ebe5b82f70fcd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Antigen presentation</topic><topic>P-glycoprotein</topic><topic>T-cell activation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pendse, Shona S.</creatorcontrib><creatorcontrib>Briscoe, David M.</creatorcontrib><creatorcontrib>Frank, Markus H.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and Applied Immunology Reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pendse, Shona S.</au><au>Briscoe, David M.</au><au>Frank, Markus H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P-glycoprotein and alloimmune T-cell activation</atitle><jtitle>Clinical and Applied Immunology Reviews</jtitle><addtitle>Clin Appl Immunol Rev</addtitle><date>2003-07-01</date><risdate>2003</risdate><volume>4</volume><issue>1</issue><spage>3</spage><epage>14</epage><pages>3-14</pages><issn>1529-1049</issn><eissn>1365-2567</eissn><eissn>1878-5441</eissn><abstract>P-glycoprotein (P-gp), the human multidrug resistant (MDR1) gene product and cancer multidrug resistance-associated adenosine triphosphate (ATP)-binding cassette (ABC) transporter, is physiologically expressed on peripheral blood mononuclear cells, but its role in cellular immunity is only beginning to be elucidated. A role of P-gp in the secretion of several T-cell and antigen presenting cell-derived cytokines has been described, and additional functions of the molecule have been identified in lymphocyte survival and antigen presenting cell differentiation. Taken together, these findings provide compelling evidence that P-gp serves several distinct functions in the initiation of primary immune responses, and a critical role of the molecule in functional alloimmune responses is now established. Here, we will review the current understanding of P-gp function in alloimmune T-cell activation via both T-cell and antigen presenting cell-dependent mechanisms, which is relevant to the field of clinical transplantation, where P-gp has been found to be a marker of acute and chronic allograft rejection. Indeed, current in vitro findings raise the possibility that P-gp could represent a novel therapeutic target in acute and chronic allograft rejection, the major causes of allograft dysfunction and ultimate graft loss.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>21709754</pmid><doi>10.1016/S1529-1049(03)00007-2</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1529-1049 |
ispartof | Clinical and Applied Immunology Reviews, 2003-07, Vol.4 (1), p.3-14 |
issn | 1529-1049 1365-2567 1878-5441 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3121004 |
source | ScienceDirect Freedom Collection; Wiley-Blackwell Read & Publish Collection; PubMed Central |
subjects | Antigen presentation P-glycoprotein T-cell activation |
title | P-glycoprotein and alloimmune T-cell activation |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T08%3A49%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P-glycoprotein%20and%20alloimmune%20T-cell%20activation&rft.jtitle=Clinical%20and%20Applied%20Immunology%20Reviews&rft.au=Pendse,%20Shona%20S.&rft.date=2003-07-01&rft.volume=4&rft.issue=1&rft.spage=3&rft.epage=14&rft.pages=3-14&rft.issn=1529-1049&rft.eissn=1365-2567&rft_id=info:doi/10.1016/S1529-1049(03)00007-2&rft_dat=%3Cproquest_pubme%3E1835552142%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4112-b2f302f31e1130e9aceac73892a868e2a6c33efa553262d3870ebe5b82f70fcd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1835552142&rft_id=info:pmid/21709754&rfr_iscdi=true |